Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11602536 Topical treatment of vitiligo by a JAK inhibitor

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Incyte

Current Assignee

Incyte

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

11602536

Date of Patent

March 14, 2023

Patent Application Number

16897923

Date Filed

June 10, 2020

Patent Citations

‌

US Patent 10869870 Topical formulation for a JAK inhibitor

‌

US Patent 10610530 Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile

‌

US Patent 10639310 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors

‌

US Patent 10758543 Topical formulation for a JAK inhibitor

‌

US Patent 11219624 Topical formulation for a JAK inhibitor

Patent Primary Examiner

‌

Paul V Ward

The present disclosure relates to topical treatment of vitiligo using ruxolitinib, or a pharmaceutically acceptable salt thereof.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11602536 Topical treatment of vitiligo by a JAK inhibitor

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API